/ Print /

LATEST

Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Predictive analytics reduces chemotherapy-associated hospitalizationsPatient risk can improve value-based cancer care. Find out how.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Creating a ‘robust’ specialty pharmacy networkThe correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
State medical marijuana laws continue to expandMedical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.
Five ways tech can help close healthcare gapsIt’s no surprise that gaps in the screening, monitoring, and management of chronic diseases abound, even in managed care settings. Here’s how technology can help.
Insulin treatment persistence varies among payersA study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.